Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis

Infection and Immunity

Volumn 68, Issue 1, 2000, Pages 288-293

  Murray, Henry W ^a,b   Delph Etienne, Sharmaine ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Box 130 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GAMMA INTERFERON; NITRIC OXIDE SYNTHASE; STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; KNOCKOUT MOUSE; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033964728     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.1.288-293.2000     Document Type: Article

References (49)

1. Adinolfi, L., and P. Bonventre. 1985. Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,665-1). Am. J. Trop. Med. Hyg. 34:270-277.
2. Allendoerfer, R., and G. S. Deepe. 1997. Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice. Infect. Immun. 65:2564-2569.
3. Chia, J. K. S., and M. Pollack. 1989. Amphotericin B induces tumor necrosis factor production by murine macrophages. J. Infect. Dis. 159:113-116.
4. Ibrahim, M., M. Hag-Ali, A. El-Hassan, T. Theander, and A. Kharazim. 1994. Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing, Parasitol. Res. 80:569-574.
5. Lin, H.-S., G. Medoff, and G. S. Kobayashi. 1977. Effects of amphotericin B on macrophages and their precursor cells. Antimicrob Agents Chemother. 11:154-160.
6. Lira, R., S. Sundar, A. Makharia, R. Kenney, A. Gam, E. Saraiva, and D. Sacks. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony resistant strains of Leishmania donovani. J. Infect. Dis. 180:564-567.
7. McMicking, J. D., C. Nathan, G. Hom, N. Chartrain, D. S. Fletcher, M. Trumbauer, K. Stevens, Q. Xie, K. Sokol, N. Hutchinson, H. Chen, and J. S. Mudgett. 1995. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641-650.
8. Medoff, G., J. Brajtburg, G. S. Kobayashi, and J. Bolard. 1983. Antifungal agents useful in therapy of systemic fungal infection. Annu. Rev. Pharmacol. Toxicol. 23:303-360.
9. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, and H. W. Murray. 1994. Induction of Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis, Infect. Immun. 62:1058-1063.
10. Mozaffarian, N., J. W. Berman, and A. Casadevall. 1997. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob. Agents Chemother. 41:1825-1829.
11. Murray, H. W. 1982. Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J. Immunol. 129:351-357.
12. Murray, H. W. 1990. Effect of continuous administration of interferongamma in experimental visceral leishmaniasis. J. Infect. Dis. 161:992-994.
13. Murray, H. W. 1999. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDs 13:459-465.
14. Murray, H. W. 1999. Granulomatous inflammation: host antimicrobial defense in the tissues in visceral leishmaniasis, p. 977-994. In J. I. Gallin, R. Snyderman, D. T. Fearon, B. F. Haynes, and C. F. Nathan (ed.), Inflammation: basic principles and clinical correlates. Lippincott-Raven, Philadelphia, Pa.
15. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: interferon-γ plus pentavalent antimony. J. Infect. Dis. 157:973-979.
16. Murray, H. W., A. M. Granger, and S. K. Mohanty. 1991. Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-γ- and interleukin-2-independent. J. Infect. Dis. 163:622-624.
17. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally-induced Th2 cell-associated response model. J. Exp. Med. 185:867-374.
18. Murray, H. W., J. Hariprashad, and R. E. Fichtl. 1993 Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob. Agents Chemother. 37:1504-1505.
19. Murray, H. W., J. Hariprashad, and R. Fichtl. 1996. Models of relapse of experimental visceral leishmaniasis. J. Infect. Dis. 173:1041-1043.
20. Murray, H. W., and C. F. Nathan. 1999, Macrophage microbicidal mechanisms in vivo: reactive nitrogen vs. oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
21. Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. Successful response to chemotherapy in experimental visceral leishmaniasis: requirement for T cells and effect of lymphokines. J. Clin. Investig. 83:1254-1259.
22. Nabors, G. S., and J. P. Farrell. 1996. Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment. J. Infect. Dis, 173:979-986.
23. Nathan, C. 1997. Inducible nitric oxide synthase: what difference does it make? J. Clin. Investig. 100:2417-2423.
24. Nathan, C. F., and J. B. Hibbs. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3:65-70.
25. Perfect, J. R., D. L. Granger, and D. T. Durack. 1987. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J. Infect. Dis. 156:316-323.
26. Pollack, J. D., P. A. Williams, G. Gifford, L. L. Li, X. Du, J. Fisherman, S. H. Orkin, C. M. Doershuck, and M. C. Dinhauer. 1995. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat. Genet. 9:202-208.
27. r congenic mouse strains. Infect. Immun. 59:3935-3944.
28. Rogers, P. D., J. K. Jenkins, S. W. Chapman, K. Ndebele, B. A. Chapman, and J. D. Cleary. 1998. Amphotericin B activation for human genes encoding for cytokines. J. Infect. Dis. 178:1726-1733.
29. Shiloh, M. U., J. D. MacMicking, S. Nicholson, J. E. Brause, S. Potter, M. Marino, F. Fang, M. Dinauer, and C. Nathan. 1999. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10:29-38.
30. Shiloh, M. U., and C. F. Nathan. 1999. Antimicrobial mechanisms of macrophages, p. 407-439. In S. Gordon (ed.). Phagocytosis and pathogens. JAI Press, Inc., Greenwich, Conn.
31. Sodhi, S., N. Ganguly, N. Malla, and R. Mahajan, 1989. Lymphokine mediated microbicidal activity of peritoneal macrophages from Leishmania donovani infected and drug treated BALB/c mice. Jpn. J. Exp. Med. 59:103-108.
32. Sodhi, S., S. Kaur, R. Mahajan, N. Ganguly, and N. Malla. 1992. Effect of sodium stibogluconate and pentamidine on in vitro multiplication of Leishmania donovani in peritoneal macrophages from infected and drug-treated BALB/c mice. Immunol. Cell. Biol. 70:25-31.
33. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous interferon-γ in host defense and tissue granulomatous response. J. Immunol. 143:4244-1249.
34. Stenger, S., N. Doinhauser, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501-1514.
35. + cells in experimental visceral leishmaniasis. J. Immunol. 140:3971-3976.
36. Sundar, S., N. K, Agrawal, P. R. Sinha, G. S. Horwith, and H. W. Murray. 1997. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann. Intern. Med. 127:133-137.
37. Sundar, S., S. G. Reed, S. Sharma, A. Mehrota, and H. W. Murray. 1997. Circulating Th1 cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56:522-526.
38. Sundar, S., F. Rosenkaimer, M. Lesser, and H. W. Murray. 1995. Immunochemotberapy for a systemic intracellular infection: accelerated response using interferon-γ in visceral leishmaniasis in India. J. Infect. Dis. 171:992-997.
39. Sundar, S., V. P. Singh, S. Sharma, M. K. Makharia, and H. W. Murray. 1997. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. 176:1117-1119.
40. Taylor, A., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin 12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice. J. Exp. Med. 185:1231-1239.
41. Tokuda, Y., M. Tsuji, M. Yamazaki, S. Kimura, S. Abe, and H. Yamaguchi. 1993. Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Antimicrob. Agents Chemother. 37:2228-2230.
42. Tumang, M., C. Keogh, L. L. Moldawer, R. F. Teitelbaum, J. Hariprashad, and H. W. Murray. 1994. The role and effect of tumor necrosis factor-alpha in experimental visceral leishmaniasis. J. Immunol. 153:768-775.
43. Vecchiarelli, A., G. Verducci, S. Perito, P. Puccetti, P. Marconi, and F. Bistoni. 1986. Involvement of host macrophage in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J. Antibiot. 39:846-855.
44. + effector cells default to the Th2 pathway in interferon-γ-deficient mice infected with Leishmania major. J. Exp. Med. 179:1367-1371.
45. Wilson, M. E., M. Sandor, A. M. Blum, B. Younbag, A. Metwali, D. Elliot, R. G. Lynch, and J. V. Weinstock. 1996. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231-2239.
46. Wolf, J. E., and S. E. Massof. 1990. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect. Immun. 58: 1296-1300.
47. Yamaguchi, H. S. Abe, and Y. Tokuda. 1993. Immunomodulating activity of antifungal drugs. Ann. N. Y. Acad. Sci. 685:447-457.
48. Zhou, P., G. Miller, and R. S. Seder. 1998. Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-α plays a critical role in maintaining secondary immunity in the absence of IFN-γ. J. Immunol. 160:1359-1368.
49. Zhou, P., M. C. Sieve, R. P. Tewari, and R. A. Seder. 1997. Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum. Infect. Immun. 65:936-942.